Source: https://www.federalregister.gov/documents/2014/03/25/2014-06131/implantation-or-injectable-dosage-form-new-animal-drugs-change-of-sponsor
Timestamp: 2017-08-22 23:05:17
Document Index: 413500306

Matched Legal Cases: ['ART 6', 'art 522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009556', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009556', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', 'art\n19', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009556', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009556', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009556', '§\u2009522', '§\u2009522', '§\u2009556', '§\u2009520', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009510', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522', '§\u2009522']

Federal Register :: Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor
Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor
A Rule by the Food and Drug Administration on 03/25/2014
This rule is effective March 25, 2014.
79 FR 16180
16180-16198 (19 pages)
2014-06131
https://www.federalregister.gov/d/2014-06131 https://www.federalregister.gov/d/2014-06131
This PDF is the current document as it appeared on Public Inspection on 03/24/2014 at 08:45 am.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 104 approved new animal drug applications (NADAs) and 5 approved abbreviated new animal drug applications (ANADAs) for implantation or injectable dosage form new animal drug products from Pfizer, Inc., including its several subsidiaries and divisions, to Zoetis, Inc. FDA is also amending the animal drug regulations to remove entries describing conditions of use for new animal drug products for which no NADA is approved, to make minor corrections, and to reflect a Start Printed Page 16181current format. This is being done to increase the accuracy and readability of the regulations.
Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855; 240-276-8300, steven.vaughn@fda.hhs.gov.
Pfizer, Inc., 235 East 42d St., New York, NY 10017, and its wholly owned subsidiaries Alpharma, LLC; Fort Dodge Animal Health, Division of Wyeth; Fort Dodge Animal Health, Division of Wyeth Holdings Corp.; and its division, Pharmacia & Upjohn Co., have informed FDA that they have transferred ownership of, and all rights and interest in, the 104 approved NADAs and 5 approved ANADAs in table 1 to Zoetis, Inc., 333 Portage St., Kalamazoo, MI 49007 as follows:
Table 1—NADAs and ANADAs Being Transferred From Pfizer, Inc., to Zoetis, Inc.
006-103 FOLLUTEIN (chorionic gonadotropin) Veterinary.
006-281 INTRAGEL (gelatin and sodium chloride) Injectable Solution.
006-417 RECOVR (tripelennamine hydrochloride) Injectable Solution.
008-769 LIQUAMYCIN (oxytetracycline hydrochloride) Injectable Solution.
008-932 KEMITHAL L.A. (thialbarbitone sodium) Powder for Injection.
009-576 SYNOVEX S and SYNOVEX C (progesterone and estradiol benzoate) Implants.
010-809 SURITAL (thiamylal sodium) Injectable Solution.
010-865 FERREXTRAN 100 (iron dextran complex) Injection.
011-241 Promazine HCl Injectable Solution.
011-427 SYNOVEX H (estradiol benzoate and testosterone propionate) Implants.
011-482 VETAME (Triflupromazine Hydrochloride) Injectable Solution.
011-593 Solu-Delta Cortef (prednisolone sodium succinate) Powder for Injection.
011-644 FELAC (colloidal ferric oxide) Injection.
011-789 PREDEF 2X (isoflupredone acetate) Injectable Suspension.
011-879 RUBRAFER S-100 (iron dextran complex) Injection.
011-953 BIOSOL (neomycin sulfate) Injectable Solution.
012-204 DEPO-MEDROL (methylprednisolone acetate) Injectable Suspension.
013-146 LIQUAMYCIN (oxytetracycline hydrochloride and lidocaine) Injectable Solution.
015-126 Spectinomycin Tablet and Injection.
015-147 DARBAZINE (prochlorperazine and isopropamide) Injection.
030-414 FLUCORT (flumethasone) Injectable Solution.
030-844 WINSTROL-V (stanozolol) Injectable Suspension.
031-944 DYNAMYXIN (sulfomyxin) Injectable.
033-655 S.E.Z. (sulfaethoxypyridazine) Intravenous Solution.
034-025 LINCOCIN (lincomycin hydrochloride) Injectable Solution.
034-705 EQUIPOISE (boldenone undecylenate) Injection.
036-211 ANAPRIME (flumethasone) Injectable Suspension.
036-212 FLUOSMIN (flumethasone acetate) Injectable Suspension.
038-838 ROBAXIN-V (methocarbamol) Injectable.
039-204 PROTOPAM (pralidoxime chloride) Powder for Injection.
041-245 AGRIBON (sulfadimethoxine) Injection 40%.
041-836 KANTRIM 200 (kanamycin sulfate) Injection.
043-079 CENTRINE (aminopentamide hydrogen sulfate) Injectable.
043-304 KETASET (ketamine hydrochloride) Injection.
044-611 TALWIN-V (pentazocine lactate) Injection.
045-514 EQUIBUTE (phenylbutazone) Injection.
045-716 TRANVET (propiopromazine hydrochloride) Injectable Solution.
046-788 Oxytocin Injection.
046-789 CHLOROPENT (chloral hydrate, magnesium sulfate, and pentobarbital) Injection.
046-790 Sodium Thiopental Powder for Injection.
049-553 RIPERCOL L (levamisole phosphate) Injection.
049-948 AQUACHEL 100 (oxytetracycline hydrochloride) Injectable Solution. with lidocaine.
055-064 PRINCILLIN (ampicillin trihydrate) Injection.
055-066 PRINCILLIN (ampicillin trihydrate) Injection.
055-071 PRINCILLIN (ampicillin trihydrate) Injection.
055-079 AMPI-JECT (ampicillin trihydrate) Injectable Suspension.
055-084 AMP-EQUINE (ampicillin sodium) Powder for Injection.
055-089 AMOXI-INJECT (amoxicillin trihydrate) Injectable Suspension. (for Cattle).
055-091 AMOXI-INJECT (amoxicillin trihydrate) Injectable Suspension. (for Dogs and Cats).
065-087 LONGICIL Fortified (penicillin G benzathine and penicillin G procaine) Suspension.
065-130 CRYSTALLINE (penicillin G procaine) Injectable Suspension.
065-169 FLO-CILLIN (penicillin G benzathine penicillin G procaine) Injectable Suspension.
065-174 CRYSTALLINE (penicillin G procaine) Injectable Suspension.
065-463 MYCHEL-VET (chloramphenicol) Injection.
065-483 PFIZER-STREP (dihydrostreptomycin sulfate) Injection.
091-127 RACHELLE OXYVET (oxytetracycline hydrochloride) Injection.
091-192 RENOGRAFIN-76 (diatrizoate meglumine and diatrizoate sodium) Injection.
091-240 RENOVIST (diatrizoate meglumine and diatrizoate sodium) Injection.
092-116 KETASET Plus (ketamine hydrochloride, promazine hydrochloride, and aminopentamide hydrogen sulfate) Injection.
094-114 LIQUAMYCIN 100 (oxytetracycline hydrochloride) Injectable Solution.
096-675 EQUIPROXEN (naproxen) 10% Injectable Solution.
Start Printed Page 16182
098-640 ROBIZONE (phenylbutazone) Injectable Solution. 20%.
099-402 AQUACHEL 100 (oxytetracycline hydrochloride) Injectable Solution.
100-202 PROSTIN F2 Alpha (dinoprost tromethamine) Injectable Solution.
100-254 SYNCHROCEPT (prostalene) Injectable Solution.
100-703 CARBOCAINE-V (mepivacaine hydrochloride) Injectable Solution.
101-777 ROBINUL-V (glycopyrrolate) Injectable.
102-437 TRAMISOL (levamisole phosphate) Injectable Solution.
102-990 TORBUTROL (butorphanol tartrate) Injection.
104-184 STYQUIN (butamisole hydrochloride) Injectable Solution.
106-111 TELAZOL (tiletamine hydrochloride and zolazepam hydrochloride) for Injection.
108-901 LUTALYSE (dinoprost tromethamine) Injectable Solution.
111-369 Dexamethasone Sterile Solution.
112-048 HYLARTIN V (hyaluronate sodium) Injection.
113-232 LIQUAMYCIN LA-200 (oxytetracycline hydrochloride) Injectable Solution.
128-549 BOVILENE (fenprostalene) Injection.
128-967 REPOSE (dibucaine hydrochloride and secobarbital sodium) Euthanasia Solution.
130-660 DEXACHEL (dexamethasone) Injection.
132-486 DI-TRIM (trimethoprim and sulfadiazine) 24% Injectable Suspension.
134-778 DI-TRIM (trimethoprim and sulfadiazine) 48% Injectable Suspension.
135-780 TORBUGESIC (butorphanol tartrate) Injection.
136-651 GUAILAXIN (guaifenesin) Powder for Injection.
138-903 PORCILENE (fenprostalene) Injection.
139-237 FACTREL (gonadorelin hydrochloride) Injection.
139-913 EQURON (hyaluronate sodium) Injection.
140-269 KETOFEN (ketoprofen) Injection.
140-338 NAXCEL (ceftiofur sodium) Sterile Powder for Injection.
140-890 EXCENEL RTU (ceftiofur hydrochloride) Injectable Suspension.
141-043 SYNOVEX Choice or SYNOVEX Plus (trenbolone acetate and estradiol benzoate) Implants.
141-047 TORBUGESIC-SA (butorphanol tartrate) Injection.
141-061 DECTOMAX (doramectin) Injectable Solution.
141-069 FIRST GUARD (colistimethate sodium) Sterile Powder.
141-077 ADSPEC (spectinomycin sulfate tetrahydrate) Sterile Solution.
141-189 PROHEART 6 (moxidectin) Injectable Suspension.
141-199 RIMADYL (carprofen) Injectable Solution.
141-207 ADVOCIN (danofloxacin) Injectable Solution.
141-209 EXCEDE (ceftiofur crystalline free acid) Injectable Suspension.
141-235 EXCEDE (ceftiofur crystalline free acid) Injectable Suspension. for Swine.
141-244 DRAXXIN (tulathromycin) Injectable Solution.
141-263 CERENIA (maropitant) Injectable Solution.
141-285 CONVENIA (cefovecin sodium) Powder for Injection.
141-288 EXCENEL (ceftiofur hydrochloride) Injectable Suspension.
141-303 PROPOCLEAR (propofol).
141-322 IMPROVEST (gonadotropin releasing factor-diphtheria toxoid conjugate) Injection.
200-109 VELENIUM (vitamin E and sodium selenite) Injection.
200-127 PROSPEC (spectinomycin sulfate tetrahydrate) Injectable Solution.
200-142 Flunixin Meglumine Solution.
200-274 Lincomycin Injectable Solution. 30%.
200-367 SYNOVEX T120, T40, or T80 (trenbolone acetate and estradiol) Implants.
Accordingly, the Agency is amending the regulations in 21 CFR part 522 to reflect these transfers of ownership. In addition, the regulations are being amended to make minor corrections and to reflect a current format. This is being done to increase the accuracy and readability of the regulations.
2. In § 522.23, remove paragraphs (d) and (e); and revise paragraphs (b) and (c) to read as follows:
§ 522.23
(b) Sponsors. See Nos. 000010 and 000859 in § 510.600(c) of this chapter:
(c) Conditions of use in dogs, cats, and horses—(1) Amount. Dogs: 0.25 to 0.5 mg per pound (/lb) of body weight; Cats: 0.5 to 1.0 mg/lb of body weight; Horses: 2.0 to 4.0 mg per 100 lbs of body weight.
(2) Indications for use. For use as a tranquilizer and as a preanesthetic agent.
§ 522.44
3. Remove § 522.44. Start Printed Page 16183
4. Revise paragraph (b) of § 522.56 to read as follows:
§ 522.56
(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.
5. Revise § 522.62 to read as follows:
§ 522.62
Aminopentamide.
(a) Specifications. Each milliliter of solution contains 0.5 milligram (mg) aminopentamide hydrogen sulfate.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—(1) Amount. Administer by subcutaneous or intramuscular injection every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; For animals weighing 11 to 20 lbs: 0.2 mg; For animals weighing 21 to 50 lbs: 0.3 mg; For animals weighing 51 to 100 lbs: 0.4 mg; For animals weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use, dosage may be continued by oral administration of tablets.
(2) Indications for use. For the treatment of vomiting and/or diarrhea, nausea, acute abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.
6. Revise § 522.82 to read as follows:
§ 522.82
Aminopropazine.
(a) Specifications. Each milliliter of solution contains aminopropazine fumarate equivalent to 25 milligrams (mg) aminopropazine base.
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs and cats—(i) Amount. 1 to 2 mg per pound of body weight, repeated every 12 hours as indicated, by intramuscular or intravenous injection.
(ii) Indications for use. For reducing excessive smooth muscle contractions, such as occur in urethral spasms associated with urolithiasis.
(2) Horses—(i) Amount. Administer 0.25 mg per pound of body weight, repeated every 12 hours as indicated, by intramuscular or intravenous injection.
(ii) Indications for use. For reducing excessive smooth muscle contractions, such as occur in colic spasms.
(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
7. Revise § 522.84 to read as follows:
§ 522.84
Beta-aminopropionitrile.
(a) Specifications. The drug is a sterile powder. Each milliliter of constituted solution contains 0.7 milligrams (mg) beta-aminopropionitrile fumarate.
(b) Sponsor. See No. 064146 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer 7 mg by intralesional injection every other day for five treatments beginning about 30 days after initial injury.
(2) Indications for use in horses. For treatment of tendinitis of the superficial digital flexor tendon (SDFT) in horses where there is sonographic evidence of fiber tearing.
8. Revise § 522.88 to read as follows:
§ 522.88
(a) Specifications—(1) Each vial contains 3 grams (g) of amoxicillin trihydrate. Each milliliter of constituted suspension contains 100 or 250 milligrams (mg) amoxicillin trihydrate for use as in paragraph (d)(1) of this section.
(2) Each vial contains 25 g of amoxicillin trihydrate. Each milliliter of constituted suspension contains 250 mg amoxicillin trihydrate for use as in paragraph (d)(2) of this section.
(c) Related tolerance. See § 556.38 of this chapter.
(d) Conditions of use—(1) Dogs and cats—(i) Amount. Administer 5 mg per pound of body weight daily for up to 5 days by intramuscular or subcutaneous injection.
(ii) Indications for use—(A) Dogs. For treatment of infections caused by susceptible strains of organisms as follows: Respiratory infections (tonsillitis, tracheobronchitis) due to Staphylococcus aureus, Streptococcus spp., Escherichia coli, and Proteus mirabilis; genitourinary infections (cystitis) due to S. aureus, Streptococcus spp., E. coli, and P. mirabilis; gastrointestinal infections (bacterial gastroenteritis) due to S. aureus, Streptococcus spp., E. coli, and P. mirabilis; bacterial dermatitis due to S. aureus, Streptococcus spp., and P. mirabilis; soft tissue infections (abscesses, lacerations, and wounds), due to S. aureus, Streptococcus spp., E. coli, and P. mirabilis.
(B) Cats. For treatment of infections caused by susceptible strains of organisms as follows: Upper respiratory infections due to S. aureus, Staphylococcus spp., Streptococcus spp., Haemophilus spp., E. coli, Pasteurella spp., and P. mirabilis; genitourinary infections (cystitis) due to S. aureus, Streptococcus spp., E. coli, P. mirabilis, and Corynebacterium spp.; gastrointestinal infections due to E. coli, Proteus spp., Staphylococcus spp., and Streptococcus spp.; skin and soft tissue infections (abscesses, lacerations, and wounds) due to S. aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella multocida.
(2) Cattle—(i) Amount. Administer 3 to 5 mg per pound of body weight daily for up to 5 days by intramuscular or subcutaneous injection.
(ii) Indications for use. For treatment of diseases due to amoxicillin-susceptible organisms as follows: Respiratory tract infections (shipping fever, pneumonia) due to P. multocida, P. hemolytica, Haemophilus spp., Staphylococcus spp., and Streptococcus spp. and acute necrotic pododermatitis (foot rot) due to Fusobacterium necrophorum.
(iii) Limitations. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
9. Revise § 522.90 to read as follows:
§ 522.90
Ampicillin injectable dosage forms.
10. Revise § 522.90a to read as follows:
§ 522.90a
Ampicillin trihydrate suspension.
(a) Specifications. (1) Each milliliter contains ampicillin trihydrate equivalent to 200 milligrams (mg) of ampicillin.
(2) Each milliliter contains ampicillin trihydrate equivalent to 150 mg of ampicillin.
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter.
(1) No. 054771 for use of product described in paragraph (a)(1) as in paragraphs (d)(1), (d)(2), (d)(3)(i)(A), (d)(3)(ii)(A), (d)(3)(iii), and (d)(4) of this section.
(2) No. 054771 for use of product described in paragraph (a)(2) as in Start Printed Page 16184paragraphs (d)(3)(i)(B), (d)(3)(ii)(B), and (d)(3)(iii) of this section.
(c) Related tolerances. See § 556.40 of this chapter.
(d) Conditions of use—(1) Cattle—(i) Amount. For enteritis: 3 mg per pound of body weight, intramuscularly, once or twice daily, for up to 3 days. For pneumonia: 3 mg per pound of body weight, intramuscularly, twice daily, for up to 3 days.
(ii) Indications for use. For treatment of bacterial enteritis in calves caused by Escherichia coli and bacterial pneumonia caused by Pasteurella spp. susceptible to ampicillin.
(iii) Limitations. Treated animals must not be slaughtered for food use during treatment or for 9 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Swine—(i) Amount. 3 mg per pound of body weight by intramuscular injection, once or twice daily, for up to 3 days.
(ii) Indications for use. Treatment of bacterial enteritis (colibacillosis) caused by E. coli and bacterial pneumonia caused by Pasteurella spp. susceptible to ampicillin.
(iii) Limitations. Treated animals must not be slaughtered for food use during treatment or for 15 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(3) Dogs—(i) Amount—(A) 3 to 6 mg per pound of body weight by intramuscular injection, once or twice daily. Usual treatment is 3 to 5 days.
(B) 3 to 5 mg of ampicillin per pound of body weight, once a day for up to 4 days.
(ii) Indications for use—(A) Treatment of respiratory tract infections due to E. coli, Pseudomonas spp., Proteus spp., Staphylococcus spp., and Streptococcus spp.; tonsillitis due to E. coli, Pseudomonas spp., Streptococcus spp., and Staphylococcus spp.; generalized infections (septicemia) associated with abscesses, lacerations, and wounds due to Staphylococcus spp. and Streptococcus spp.
(B) Treatment of bacterial infections of the upper respiratory tract (tonsillitis) due to Streptococcus spp., Staphylococcus spp., E. coli, Proteus spp., and Pasteurella spp., and soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus spp., Streptococcus spp., and E. coli, when caused by susceptible organisms.
(4) Cats—(i) Amount. 5 to 10 mg per pound of body weight by intramuscular or subcutaneous injection, once or twice daily. Usual treatment is 3 to 5 days.
(ii) Indications for use. Treatment of generalized infections (septicemia) associated with abscesses, lacerations, and wounds due to Staphylococcus spp., Streptococcus spp., and Pasteurella spp.
11. In § 522.90b, revise the section heading to read as follows:
§ 522.90b
Ampicillin trihydrate powder for injection.
§ 522.90c
12. In paragraph (b) of § 522.90c, remove “000069 and 010515” and in its place add “010515 and 054771”.
13. Revise § 522.144 to read as follows:
§ 522.144
Arsenamide.
(a) Specifications. Each milliliter of solution contains 10.0 milligrams arsenamide sodium.
(c) Conditions of use in dogs—(1) Amount. Administer 0.1 milliliter (mL) per pound of body weight (1.0 mL for every 10 pounds) by intravenous injection twice a day for 2 days.
(2) Indications for use. For the treatment and prevention of canine heartworm disease caused by Dirofilaria immitis.
14. Revise § 522.161 to read as follows:
§ 522.161
(a) Specifications. Each milliliter of suspension contains:
(1) Betamethasone acetate equivalent to 10.8 milligrams (mg) betamethasone and betamethasone disodium phosphate equivalent to 3 mg of betamethasone.
(2) Betamethasone dipropionate equivalent to 5 mg betamethasone and betamethasone sodium phosphate equivalent to 2 mg of betamethasone.
(b) Sponsor. See sponsor numbers in § 510.600(c) of this chapter:
(1) No. 000061 for product described in paragraph (a)(1) of this section for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(iii) of this section.
(2) No. 000061 for product described in paragraph (a)(2) of this section for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii)(B), and (c)(2)(iii) of this section.
(c) Conditions of use—(1) Dogs—(i) Amount. Administer by intramuscular injection 0.25 to 0.5 milliliter (mL) per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of four injections.
(ii) Indications for use. As an aid in the control of pruritus associated with dermatoses.
(2) Horses—(i) Amount. Administer 2.5 to 5 mL by intra-articular injection.
(ii) Indications for use—(A) For the treatment of various inflammatory joint conditions; for example, acute and traumatic lameness involving the carpel and fetlock joints.
(B) As an aid in the control of inflammation associated with various arthropathies.
§ 522.204
15. In paragraph (b) of § 522.204, remove “053501” and in its place add “054771”.
16. Revise § 522.234 to read as follows:
§ 522.234
Butamisole.
(a) Specifications. Each milliliter of solution contains 11 milligrams (mg) butamisole hydrochloride.
(b) Sponsors. See Nos. 000859 and 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. Administer 0.1 mg per pound of body weight by subcutaneous injection. In problem cases, retreatment for whipworms may be necessary in approximately 3 months. For hookworms, a second injection should be given 21 days after the initial treatment.
(2) Indications for use. For the treatment of infections with whipworms (Trichuris vulpis), and the hookworm (Ancylostoma caninum).
§ 522.246
17. In paragraph (b)(1) of § 522.246, remove “000856” and in its place add “054771”.
18. In § 522.275, revise the section heading to read as follows:
§ 522.275
N-Butylscopolammonium.
Start Printed Page 16185 Start Amendment Part
19. Revise § 522.300 to read as follows:
§ 522.300
(a) Specifications. Each milliliter of solution contains 3 milligrams (mg) carfentanil citrate.
(b) Sponsor. See No. 053923 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. Administer 5 to 20 micrograms per kilogram (0.005 to 0.020 mg per kilogram) of body weight into large muscle of the neck, shoulder, back, or hindquarter.
(2) Indications for use. For immobilizing free ranging and confined members of the family Cervidae (deer, elk, and moose).
(3) Limitations. Do not use in domestic animals intended for food. Do not use 30 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian. The licensed veterinarian shall be a veterinarian engaged in zoo and exotic animal practice, wildlife management programs, or research.
§ 522.304
20. In paragraph (b) of § 522.304, remove “000069” and in its place add “054771”.
§ 522.311
21. In paragraph (b) of § 522.311, remove “000069” and in its place add “054771”.
§ 522.313a
22. In paragraph (b) of § 522.313a, remove “000009” and in its place add “054771”.
§ 522.313c
23. In paragraph (b) of § 522.313c, remove “000009, 000409, and 068330” and in its place add “000409, 054771, and 068330”.
24. Revise § 522.380 to read as follows:
§ 522.380
Chloral hydrate, pentobarbital, and magnesium sulfate.
(a) Specifications. Each milliliter of solution contains 42.5 milligrams (mg) of chloral hydrate, 8.86 mg of pentobarbital, and 21.2 mg of magnesium sulfate.
(c) Conditions of use—(1) Amount. For general anesthesia: Administer 20 to 50 milliliters per 100 pounds of body weight by intravenous injection until the desired effect is produced. Cattle usually require a lower dosage on the basis of body weight. As a sedative-relaxant: Administer at a level of one-fourth to one-half of the anesthetic dosage level.
(2) Indications for use. For general anesthesia and as a sedative-relaxant in cattle and horses.
25. In § 522.390, revise the section heading and paragraphs (a), (b), and (c)(3) to read as follows:
§ 522.390
(a) Specifications. Each milliliter of solution contains 100 milligrams of chloramphenicol.
(b) Sponsor. See Nos. 000859 and 054771 in § 510.600(c) of this chapter.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.
26. Revise § 522.460 to read as follows:
§ 522.460
Cloprostenol.
(a) Specifications. Each milliliter of solution contains cloprostenol sodium equivalent to:
(1) 125 micrograms (µg) of cloprostenol; or
(2) 250 μg of cloprostenol.
(b) Sponsors. See sponsors in § 510.600(c) of this chapter.
(1) No. 000061 for use of product described in paragraph (a)(1) of this section as in paragraphs (c)(1)(i) and (c)(2) of this section.
(2) Nos. 000061 and 068504 for use of product described in paragraph (a)(2) as in paragraphs (c)(1)(ii), (c)(1)(iii), and (c)(2) of this section.
(c) Conditions of use in cattle—(1) Amount and indications for use—(i) Administer 375 µg by intramuscular injection to induce abortion in pregnant feedlot heifers from 1 week after mating until 4 1/2 months of gestation.
(ii) Administer 500 μg by intramuscular injection for terminating unwanted pregnancies from mismatings from 1 week after mating until 5 months after conception; for treating unobserved (nondetected) estrus, mummified fetus, and luteal cysts; and for the treatment of pyometra.
(iii) Administer 500 μg by intramuscular injection as a single injection regimen or double injection regimen with a second injection 11 days after the first, for scheduling estrus and ovulation to control the time at which cycling cows or heifers can be bred.
(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.468
27. In paragraph (b) of § 522.468, remove “046573” and in its place add “054771”.
28. Revise § 522.480 to read as follows:
§ 522.480
(a) Specifications. Each milliliter of aqueous solution contains 40 or 80 U.S.P. (I.U.) units of repository corticotropin.
(b) Sponsor. See sponsors in § 510.600(c) of this chapter.
(1) No. 061623 for use as in paragraphs (c)(1) and (2) of this section.
(2) No. 026637 for use as in paragraph (c)(2) and (3) of this section.
(c) Conditions of use—(1) Dogs—(i) Amount. Administer one unit per pound of body weight by intramuscular injection.
(ii) Indications for use. As a diagnostic aid to test for adrenal dysfunction.
(2) Dogs and cats—(i) Amount. Administer one unit per pound of body weight by intramuscular or subcutaneous injection, to be repeated as indicated.
(ii) Indications for use. For stimulation of the adrenal cortex where there is a general deficiency of corticotropin (ACTH).
(3) Cattle—(i) Amount. Administer 200 to 600 units by intramuscular or subcutaneous injection as an initial dose, followed by a dose daily or every other day of 200 to 300 units.
(ii) Indications for use. As a therapeutic agent for primary bovine ketosis; and for stimulation of the adrenal cortex where there is a general deficiency of ACTH.
29. In paragraph (b) of § 522.522, remove “000069” and in its place add “054771”.
30. Amend § 522.535 as follows:
a. Redesignate paragraph (d) as paragraph (c);
b. Revise the section heading, and paragraphs (a) and newly designated (c)(1)(iii).
Start Printed Page 16186
§ 522.535
(a) Specifications. Each milliliter of suspension contains 25 milligrams of desoxycorticosterone pivalate.
31. Revise § 522.536 to read as follows:
§ 522.536
Detomidine.
(a) Specification. Each milliliter of solution contains 10 milligrams of detomidine hydrochloride.
(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. For sedation, analgesia, or sedation and analgesia: 20 or 40 micrograms per kilogram (0.2 or 0.4 milliliter per 100 kilogram or 220 pounds) by body weight, depending on depth and duration required. For sedation, administer by intraveneous (IV) or intramuscular (IM) injection; for analgesia, administer by IV injection; for both sedation and analgesia, administer by IV injection.
(2) Indication for use. As a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.
32. Amend § 522.540 as follows:
a. In paragraph (d)(2)(i), remove “000069 and 000859” and in its place add “000859 and 054771”;
b. In paragraph (d)(2)(ii), remove “000069” and in its place add “054771”; and
c. Revise the section heading and paragraphs (a)(3)(iii), (b)(1), (b)(3), (c)(1), (c)(3), (d)(1), (d)(3), (e)(1), and (e)(3).
§ 522.540
Dexamethasone solution.
(b)(1) Specifications. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg dexamethasone).
(3) Conditions of use—(i) Amount. Administer 0.25 to 1 mg by intravenous injection, repeated for 3 to 5 days or until a response is noted.
(ii) Indications for use. For use in dogs for the treatment of inflammatory conditions, as supportive therapy in canine posterior paresis, as supportive therapy before or after surgery to enhance recovery of poor surgical risks, and as supportive therapy in nonspecific dermatosis.
(c)(1) Specifications. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg of dexamethasone).
(3) Conditions of use—(i) Amount. Administer 2.5 to 5.0 mg by intravenous injection.
(ii) Indications for use. For use in horses as a rapid adrenal glucocorticoid and/or anti-inflammatory agent.
(d)(1) Specifications. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg of dexamethasone).
(3) Conditions of use—(i) Amount. Administer by intravenous or intramuscular injection as follows:
(A) Dogs: 0.25 to 1 mg.
(B) Cats: 0.125 to 0.5 mg.
(C) Horses: 2.5 to 5 mg.
(ii) Indications for use. For use in dogs, cats, and horses as an anti-inflammatory agent.
(e)(1) Specifications. Each milliliter of solution contains 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg dexamethasone).
(3) Conditions of use—(i) Amount. Administer by intravenous injection as follows:
(A) Dogs: 0.25 to 1 mg; may be repeated for 3 to 5 days.
(B) Horses: 2.5 to 5 mg.
(ii) Indications for use. For use in dogs and horses for glucocorticoid and anti-inflammatory effect.
33. Revise § 522.542 to read as follows:
§ 522.542
Dexamethasone suspension.
(a) Specifications. Each milliliter of suspension contains 1 milligram (mg) of dexamethasone-21-isonicotinate.
(b) Sponsor. No. 000010 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. Administer by intramuscular injection as follows: Dogs: 0.25 to 1 mg; cats: 0.125 to 0.5 mg; horses: 5 to 20 mg. Dosage may be repeated.
(2) Indications for use. For the treatment of various inflammatory conditions associated with the musculoskeletal system in dogs, cats, and horses.
34. Revise § 522.563 to read as follows:
§ 522.563
(a) Specifications. Each milliliter of solution contains 34.3 percent diatrizoate meglumine and 35 percent diatrizoate sodium, or 66 percent diatrizoate meglumine and 10 percent diatrizoate sodium.
(c) Conditions of use in dogs and cats— (1) Amount. For excretion urography, administer 0.5 to 1.0 milliliter (mL) per pound of body weight to a maximum of 30 mL intravenously. For cystography, remove urine, administer 5 to 25 mL directly into the bladder via catheter. For urethrography, administer 1.0 to 5 mL via catheter into the urethra to provide desired contrasts delineation. For angiocardiography (including aortography) rapidly inject 5 to 10 mL directly into the heart via catheter or intraventricular puncture. For cerebral angiography, rapid injection of 3 to 10 mL via carotid artery. For peripheral arteriography and/or venography and selective coronary arteriography, rapidly inject 3 to 10 mL intravascularly into the vascular bed to be delineated. For lymphography, slowly inject 1.0 to 10 mL directly into the lymph vessel to be delineated. For arthrography, slowly inject 1.0 to 5 mL directly into the joint to be delineated. For discography, slowly inject 0.5 to 1.0 mL directly into the disc to be delineated. For sialography, slowly inject 0.5 to 1.0 mL into the duct to be delineated. For Start Printed Page 16187delineation of fistulous tracts, slowly inject quantity necessary to fill the tract. For delineation of peritoneal hernias, inject 0.5 to 1.0 mL per pound of body weight directly into the peritoneal cavity.
(2) Indications for use. For visualization in excretion urography, including renal angiography, uretography, cystography, and urethrography; aortography; angiocardiography, peripheral arteriography, and venography; selective coronary arteriography; cerebral angiography; lymphography; arthrography; discography; and sialography; and as an aid in delineating peritoneal hernias and fistulous tracts.
35. In § 522.650, revise paragraphs (b), (c), (d)(1), and (d)(3) to read as follows:
§ 522.650
Dihydrostreptomycin sulfate injection.
(b) Sponsors. See Nos. 054771 and 055529 in § 510.600(c) of this chapter.
(c) Related tolerance. See § 556.200 of this chapter.
(1) Amount. Administer 5 milligrams per pound of body weight by deep intramuscular injection every 12 hours, for 3 to 5 days or until the urine is free of leptospira for at least 72 hours as measured by darkfield microscopic examination.
(3) Limitations. Discontinue use 30 days before slaughter for food. Not for use in animals producing milk because use of the drug will contaminate the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
36. In paragraph (b) of § 522.690, remove “000009” and in its place add “054771”.
37. Revise § 522.723 to read as follows:
§ 522.723
Diprenorphine.
(a) Specifications. Each milliliter of solution contains 2 milligrams of diprenorphine hydrochloride.
(b) Sponsors. See No. 053923 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. It is administered intramuscularly or intravenously at a suitable dosage level depending upon the species.
(2) Indications for use. The drug is used for reversing the effects of etorphine hydrochloride injection, veterinary, the use of which is provided for in § 522.883, in wild and exotic animals.
(3) Limitations. For use in wild or exotic animals only. Do not use in domestic food-producing animals. Do not use 30 days before, or during, the hunting season in free-ranging wild animals that might be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Distribution is restricted to veterinarians engaged in zoo and exotic animal practice, wildlife management programs, and researchers.
§ 522.770
38. In § 522.770, in paragraph (a), remove “sterile aqueous”; and in paragraph (b), remove “000069” and in its place add “054771”.
§ 522.778
39. Remove § 522.778.
40. Revise § 522.784 to read as follows:
§ 522.784
Doxylamine.
(a) Specifications. Each milliliter contains 11.36 milligrams (mg) of doxylamine succinate.
(c) Conditions of use—(1) Amount—(i) Horses: Administer 25 mg per hundred pounds of body weight by intramuscular, subcutaneous, or slow intravenous injection.
(ii) Dogs and cats: Administer 0.5 to 1 mg per pound of body weight by intramuscular or subcutaneous injection. Doses may be repeated at 8 to 12 hours, if necessary, to produce desired effect.
(2) Indications for use. For use in conditions in which antihistaminic therapy may be expected to alleviate some signs of disease in horses, dogs, and cats.
41. Revise § 522.800 to read as follows:
§ 522.800
Droperidol and fentanyl.
(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of droperidol and 0.4 mg of fentanyl citrate.
(c) Conditions of use—(1) Amount.
(i) For analgesia and tranquilization, administer as follows:
(A) 1 milliliter (mL) per 15 to 20 pounds (lbs) of body weight by intramuscular injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight; or
(B) 1 mL per 25 to 60 lbs of body weight by intravenous injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight.
(ii) For general anesthesia, administer as follows:
(A) Administer 1 mL per 40 lbs of body weight by intramuscular injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight and followed in 10 minutes by an intravenous administration of sodium pentobarbital at the rate of 3 mg per pound of body weight; or
(B) Administer 1 mL per 25 to 60 lbs of body weight by intravenous injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight and followed within 15 seconds by an intravenous administration of sodium pentobarbital at the rate of 3 mg per pound of body weight.
(2) Indications for use. As an analgesic and tranquilizer and for general anesthesia.
42. In § 522.820, redesignate paragraphs (a) and (b) as paragraphs (b) and (a) respectively; and revise paragraphs (d)(1) introductory text, (d)(2) introductory text, and (d)(3) introductory text to read as follows:
§ 522.820
(1) Dog. Administer product described in paragraph (a)(1) of this section as follows:
(2) Cats. Administer product described in paragraph (a)(1) of this section as follows:
(3) Cattle. Administer products described in paragraph (a) of this section as follows:
43. In paragraph (a)(1) of § 522.842, remove “000856” and in its place add “054771”.
44. Revise § 522.863 to read as follows:
§ 522.863
Ethylisobutrazine.
(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of ethylisobutrazine hydrochloride.Start Printed Page 16188
(c) Conditions of use in dogs—(1) Amount. Administer 2 to 5 mg per pound of body weight by intramuscular injection for profound tranquilization. Administer 1 to 2 mg per pound of body weight by intravenous injection to effect.
(2) Indications for use. For use as a tranquilizer.
45. Revise § 522.883 to read as follows:
§ 522.883
(a) Specifications. Each milliliter of solution contains 1 milligram of etorphine hydrochloride.
(c) Special considerations. Distribution is restricted to veterinarians engaged in zoo and exotic animal practice, wildlife management programs, and researchers.
(d) Conditions of use—(1) Amount. Administered intramuscularly by hand syringe or syringe dart at a suitable dosage level depending upon the species.
(2) Indications for use. For the immobilization of wild and exotic animals.
(3) Limitations. Do not use in domestic food-producing animals. Do not use 30 days before, or during, the hunting season in free-ranging wild animals that might be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.900
46. In paragraph (b)(2) of § 522.900, remove “000856” and in its place add “054771”.
47. Revise § 522.914 to read as follows:
§ 522.914
Fenprostalene.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section; and for use of product described in paragraph (a)(2) as in paragraph (e)(2) of this section.
(c) Related tolerances. See § 556.277 of this chapter.
48. Revise § 522.960 to read as follows:
§ 522.960
Flumethasone injectable dosage forms.
49. Revise § 522.960a to read as follows:
§ 522.960a
Flumethasone suspension.
(a) Specifications. Each milliliter of suspension contains 2 milligrams (mg) of flumethasone.
(c) Conditions of use in horses—(1) Amount. Administer 6 to 10 mg by intra-articular injection. Dosage is limited to a single injection per week in any one synovial structure.
(2) Indications for use. For use in the various disease states involving synovial structures (joints) of horses where excessive synovial fluid of inflammatory origin is present and where permanent structural changes do not exist. Such conditions include arthritis, carpitis, and osselets.
50. Revise § 522.960b to read as follows:
§ 522.960b
Flumethasone acetate solution.
(a) Specifications. Each milliliter of solution contains 2 milligrams (mg) of flumethasone acetate.
(c) Conditions of use in dogs—(1) Amount. Administer by intramuscular injection as follows: Dogs weighing up to 10 pounds (lbs): 2 mg; dogs weighing 10 to 25 lbs: 4 mg; dogs weighing over 25 lbs: 8 mg. Dosage should be adjusted according to the weight of the animal, the severity of the symptoms, and the response noted. Dosage by injection should not exceed 3 days of therapy. With chronic conditions intramuscular therapy may be followed by oral administration of flumethasone tablets at a daily dose of from 0.0625 to 0.25 mg per animal.
(2) Indications for use. For use in certain acute and chronic canine dermatoses of varying etiology to help control the pruritus, irritation, and inflammation associated with these conditions.
51. Revise § 522.960c to read as follows:
§ 522.960c
Flumethasone solution.
(a) Specifications. Each milliliter of solution contains 0.5 milligrams (mg) of flumethasone.
(c) Conditions of use. It is used as follows:
(1) Horses—(i) Amount. Administer 1.25 to 2.5 milligrams (mg) daily by intravenous, intramuscular, or intra-articular injection.
(ii) Indications for use. For use in the treatment of musculoskeletal conditions due to inflammation, where permanent structural changes do not exist, e.g., bursitis, carpitis, osselets, and myositis; and allergic states, e.g., hives, urticaria, and insect bites.
(2) Dogs—(i) Amount. Administer 0.0625 to 0.25 mg daily by intravenous, intramuscular, or subcutaneous injection; 0.125 to 1.0 mg daily by intra-lesional injection, depending on the size and location of the lesion; or 0.166 to 1.0 mg daily by intra-articular injection, depending on the severity of the condition and the size of the involved joint.
(ii) Indications for use. For use in the treatment of musculoskeletal conditions Start Printed Page 16189due to inflammation of muscles or joints and accessory structures where permanent structural changes do not exist, e.g., arthritis, osteoarthritis, disc syndrome, and myositis (in septic arthritis, appropriate antibacterial therapy should be concurrently administered); certain acute and chronic dermatoses of varying etiology to help control associated pruritus, irritation, and inflammation; otitis externa in conjunction with topical medication; allergic states, e.g., hives, urticaria, and insect bites; and shock and shock-like states by intravenous administration.
(3) Cats—(i) Amount. Administer 0.03125 to 0.125 mg daily by intravenous, intramuscular, or subcutaneous injection.
(ii) Indications for use. For use in the treatment of certain acute and chronic dermatoses of varying etiology to help control associated pruritus, irritation, and inflammation.
§ 522.970
52. In paragraph (b)(2) of § 522.970, remove “000856” and in its place add “054771”.
53. Revise § 522.995 to read as follows:
§ 522.995
(a) Specifications. Each milliliter of solution contains fluprostenol sodium equivalent to 50 micrograms (µg) of fluprostenol.
(c) Conditions of use in horses—(1) Amount. Administer 0.55 µg fluprostenol per kilogram of body weight by intramuscular injection.
(2) Indications for use. For use in mares for its luteolytic effect to control the timing of estrus in estrous cycling and in clinically anestrous mares that have a corpus luteum.
54. In § 522.1010, revise paragraphs (d)(2)(i)(B) and (d)(2)(ii)(B) to read as follows:
§ 522.1010
(B) Limitations. Do not use in horses intended for human consumption.
55. Revise § 522.1020 to read as follows:
§ 522.1020
(a) Specifications. Each 100 milliliters contains 8 grams of gelatin in a 0.85 percent sodium chloride solution.
(c) Conditions of use—(1) Amount. The exact dosage to be administered must be determined after evaluating the animal's condition and will vary according to the size of the animal and the degree of shock. A suggested dosage range for small animals such as dogs is 4 to 8 cubic centimeters per pound body weight. The suggested dosage range for large animals such as sheep, calves, cows, or horses is 2 to 4 cubic centimeters per pound of body weight.
(2) Indications for use. For use to restore circulatory volume and maintain blood pressure in animals being treated for shock.
§ 522.1066
56. In paragraph (b) of § 522.1066, remove “Nos. 000856 and 000859” and in its place add “Nos. 000859 and 054771”.
§ 522.1081
57. In paragraph (b)(1) of § 522.1081, remove “053501” and in its place add “054771”.
§ 522.1083
58. In paragraph (b) of § 522.1083, remove “000069” and in its place add “054771”; and in paragraph (c)(3), remove the first two sentences.
59. Revise § 522.1085 to read as follows:
§ 522.1085
Guaifenesin powder for injection.
(a) Specifications. The product is a sterile powder containing guaifenesin. A solution is prepared by dissolving the drug in sterile water for injection to make a solution containing 50 milligrams of guaifenesin per milliliter of solution.
(b) Sponsors. See Nos. 037990 and 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer 1 milliliter of prepared solution per pound of body weight by rapid intravenous infusion.
(2) Indications for use. For use as a muscle relaxant.
60. Revise § 522.1086 to read as follows:
§ 522.1086
Guaifenesin solution.
(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of guaifenesin and 50 mg of dextrose.
(b) Sponsors. See Nos. 000859 and 037990 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer 1 milliliter per pound of body weight by rapid intravenous infusion.
(2) Indications for use. For use as a skeletal muscle relaxant.
§ 522.1125
61. In paragraph (d)(3) of § 522.1125, remove the first two sentences.
62. Amend § 522.1145 as follows:
a. In paragraph (a)(2), remove “000009” and in its place add “054771”;
b. In paragraph (b)(2), remove “053501” and in its place add “054771”;
c. Revise the section heading and paragraphs (a)(3)(i), (a)(3)(iii), (b)(3)(i), (b)(3)(iii), (c)(3), (d)(3)(iii), (f)(3)(i), and (f)(3)(iii).
§ 522.1145
(i) Amount. Small and medium-size joints (carpal, fetlock): 20 mg; larger joint (hock): 40 mg. Treatment may be repeated at weekly intervals for a total of three treatments.
(i) Amount. Small and medium-size joints (carpal, fetlock): 10 mg; larger joint (hock): 20 mg. Treatment may be repeated at weekly intervals for a total of four treatments.
(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.Start Printed Page 16190
(3) Conditions of use—(i) Amount. Small and medium-size joints (carpal, fetlock): 20 mg. Treatment may be repeated after 1 or more weeks but not to exceed 2 injections per week for a total of 4 weeks.
(ii) Indications for use. For the intra-articular treatment of carpal or fetlock joint dysfunction in horses due to acute or chronic, non-infectious synovitis associated with equine osteoarthritis.
(i) Amount. Small and medium-size joints (carpal, fetlock): 22 mg; larger joint (hock): 44 mg. Treatment may be repeated at weekly intervals for a total of three treatments.
63. In § 522.1150, remove footnote 1, and revise the section heading and paragraphs (a) and (c)(3) to read as follows:
§ 522.1150
(a) Specifications. Each milliliter of solution contains 25 milligrams of hydrochlorothiazide.
(3) Limitations. Milk taken from dairy animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
64. Revise § 522.1155 to read as follows:
§ 522.1155
Imidocarb powder for injection.
(a) Specifications. The product is a sterile powder containing imidocarb dipropionate. Each milliliter of constituted solution contains 100 milligrams (mg) of imidocarb base.
(c) Special considerations. Imidocarb dipropionate is sold only under permit issued by the Director of the National Program Planning Staff, Veterinary Services, Animal and Plant Health Inspection Service, U.S. Department of Agriculture, to licensed or full-time State, Federal, or military veterinarians.
(d) Conditions of use in horses and zebras—(1) Amount. For Babesia caballi infections, administer 2 mg of imidocarb base per kilogram of body weight by intramuscular injection in the neck region, repeating dosage once after 24 hours. For Babesia equi infections, administer 4 mg of imidocarb base per kilogram of body weight by intramuscular injection in the neck region, repeating dosage four times at 72-hour intervals.
(2) Indications for use. For the treatment of babesiosis (piroplasmosis) caused by Babesia caballi and Babesia equi.
65. Revise § 522.1156 to read as follows:
§ 522.1156
Imidocarb solution.
(a) Specifications. Each milliliter of solution contains 120 milligrams (mg) of imidocarb dipropionate.
(c) Conditions of use in dogs—(1) Amount. Administer 6.6 mg per kilogram (3 mg per pound) of body weight by intramuscular injection. Repeat the dose after 2 weeks for a total of two treatments.
(2) Indications for use. For the treatment of clinical signs of babesiosis and/or demonstrated Babesia organisms in the blood.
§ 522.1182
66. In § 522.1182, in paragraph (b)(2), remove “000856” and in its place add “054771”; and in paragraphs (b)(4) introductory text and (b)(5) introductory text, remove “053501” and in its place add “054771.
67. Add § 522.1185 to read as follows:
§ 522.1185
68. Revise § 522.1204 to read as follows:
§ 522.1204
Kanamycin.
(a) Specifications. Each milliliter of solution contains 50 or 200 milligrams (mg) of kanamycin as kanamycin sulfate.
(c) Conditions of use in dogs and cats—(1) Amount. Administer by subcutaneous or intramuscular injection 5 mg per pound of body weight per day in equally divided doses at 12-hour intervals.
(2) Indications for use. For the treatment of bacterial infections due to kanamycin sensitive organisms in dogs and cats.
§ 522.1222
69. Remove § 522.1222.
Start Printed Page 16191
§ 522.1222a
[Redesignated as § 522.1222 and Amended]
70. Redesignate § 522.1222a as § 522.1222 and in newly designated § 522.1222, in paragraph (b), add “054771,” after “054668,”.
§ 522.1222b
[Redesignated as § 522.1223 and Revised]
71. Redesignate § 522.1222b as § 522.1223 and revise it to read as follows:
§ 522.1223
Ketamine, promazine, and aminopentamide.
(a) Specifications. Each milliliter of solution contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity, 7.5 (mg) of promazine hydrochloride, and 0.0625 mg of aminopentamide hydrogen sulfate.
(c) Conditions of use in cats— (1) Amount. Administer by intramuscular injection 15 to 20 mg ketamine base per pound of body weight, depending on the effect desired.
(2) Indications for use. It is used in cats as the sole anesthetic agent for ovariohysterectomy and general surgery.
72. Revise § 522.1225 to read as follows:
§ 522.1225
(a) Specifications. Each milliliter of solution contains 100 milligrams (mg) of ketoprofen.
(c) Conditions of use in horses—(1) Amount. Administer by intravenous injection 1.0 mg per pound of body weight once daily for up to 5 days.
(2) Indications for use. For alleviation of inflammation and pain associated with musculoskeletal disorders in horses.
§ 522.1228
73. Remove reserved § 522.1228.
§ 522.1244
[Redesignated as § 522.1242 and Amended]
74. Redesignate § 522.1244 as § 522.1242 and amend it as follows:
a. In paragraph (a), remove “sterile aqueous”;
b. In paragraph (b), remove “053501” and in its place add “054771”; and
c. Revise the section heading to read as follows:
§ 522.1242
§ 522.1260
75. In § 522.1260, in paragraph (b)(1), remove “000009” and in its place add “054771”; and in paragraph (b)(3), remove “046573” and in its place add “054771”.
76. Revise § 522.1289 to read as follows:
§ 522.1289
(a) Specifications. Each milliliter of suspension contains 10 milligrams (mg) of lufenuron.
(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.
(c) Conditions of use in cats—(1) Amount. 10 mg per kilogram (4.5 mg per pound) of body weight every 6 months, by subcutaneous injection.
(2) Indications for use. For control of flea populations in cats 6 weeks of age and older.
§ 522.1315
77. In paragraph (b) of § 522.1315, remove “000069” and in its place add “054771”.
78. In § 522.1335, revise the section heading and paragraphs (a) and (c)(3) to read as follows:
§ 522.1335
(a) Specifications. Each milliliter of solution contains 1.0 milligrams of medetomidine hydrochloride.
79. In § 522.1362, revise the section heading and paragraphs (c)(1) and (3) to read as follows:
§ 522.1362
Melarsomine powder for injection.
(1) Amount. Administer only by deep intramuscular injection in the lumbar muscles (L3-L5).
§ 522.1372
80. In paragraph (b) of § 522.1372, remove “000009” and in its place add “054771”.
81. Revise § 522.1380 to read as follows:
§ 522.1380
(a) Specifications. Each milliliter of solution contains 100 milligrams (mg) of methocarbamol.
(c) Conditions of use—(1) Amount—(i) Dogs and cats. Administer by intravenous injection 20 mg per pound of body weight for moderate conditions or 25 to 100 mg per pound of body weight for severe conditions (tetanus and strychnine poisoning). The total cumulative dose should not to exceed 150 mg per pound of body weight.
(ii) Horses. Administer by intravenous injection 2 to 10 mg per pound of body weight for moderate conditions or 10 to 25 mg per pound of body weight for severe conditions (tetanus). Additional amounts may be needed to relieve residual effects and to prevent recurrence of symptoms.
(2) Indications for use. As an adjunct for treating acute inflammatory and traumatic conditions of the skeletal muscles and to reduce muscular spasms.
§ 522.1410
82. In paragraph (b) of § 522.1410, remove “000009 and 054628” and in its place add “054628 and 054771”.
83. In § 522.1451, in paragraph (b), remove “000856” and in its place add “054771”; and revise the section heading to read as follows:
§ 522.1451
Moxidectin microspheres for injection.
84. In § 522.1452, revise the section heading, paragraph (a), the heading of paragraph (c), and paragraph (c)(3) to read as follows:
§ 522.1452
Nalorphine.
(a) Specifications. Each milliliter of solution contains 5 milligrams of nalorphine hydrochloride.
(c) Conditions of use in dogs—
85. In § 522.1465, in paragraph (c)(3), remove the first two sentences; and revise the section heading and paragraph (a) to read as follows:
Start Printed Page 16192
§ 522.1465
§ 522.1468
86. In paragraph (b) of § 522.1468, remove “000856” and in its place add “054771”.
87. Revise § 522.1484 to read as follows:
§ 522.1484
(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of neomycin sulfate (equivalent to 35 mg of neomycin base).
(c) Conditions of use in dogs and cats—(1) Amount. Administer 5 mg per pound of body weight daily by intramuscular or intravenous injection, divided into portions administered every 6 to 8 hours for 3 to 5 days.
(2) Indications for use. For the treatment of acute and chronic bacterial infections due to organisms susceptible to neomycin.
(3) Limitations. Not for parenteral use in food-producing animals because of prolonged residues in edible tissues. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
88. In § 522.1503, revise the section heading and paragraphs (a) and (c) to read as follows:
§ 522.1503
(a) Specifications. Each milliliter of solution contains 2 milligrams (mg) neostigmine methylsulfate.
(c) Conditions of use—(1) Amount. Administer to cattle and horses at a dosage level of 1 mg per (/) 100 pounds (lbs) of body weight subcutaneously. Administer to sheep at a dosage level of 1 to 11/2 mg/100 lbs body weight subcutaneously. Administer to swine at a dosage level of 2 to 3 mg/100 lbs body weight intramuscularly. These doses may be repeated as indicated.
(2) Indications for use. For treating rumen atony; initiating peristalsis which causes evacuation of the bowel; emptying the urinary bladder; and stimulating skeletal muscle contractions.
(3) Limitations. Not for use in animals producing milk, since this use will result in contamination of the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
89. In § 522.1610, revise the section heading and paragraphs (a) and (c) to read as follows:
§ 522.1610
Oleate sodium.
(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of sodium oleate.
(c) Conditions of use in horses—(1) Amount. Administer by parenteral injection depending on the area of response desired. An injection of 1 milliliter (mL) will produce a response of approximately 15 square centimeters. Do not inject more than 2 mL per injection site. Regardless of the number of injection sites, the total volume used should not exceed 10 mL.
(2) Indications for use. It is used in horses to stimulate infiltration of cellular blood components that subsequently differentiate into fibrous and/or fibrocartilagenous tissue.
90. In § 522.1620, revise paragraph (c) to read as follows:
§ 522.1620
Orgotein for injection.
(c) Conditions of use—(1) Horses—(i) Amount. Administer by deep intramuscular injection at a dosage level of 5 milligrams (mg) every other day for 2 weeks and twice weekly for 2 to 3 more weeks. Severe cases, both acute and chronic, may benefit more from daily therapy initially. Dosage may be continued beyond 5 weeks if satisfactory improvement has not been achieved.
(ii) Indications for use. It is used in the treatment of soft tissue inflammation associated with the musculoskeletal system.
(2) Dogs—(i) Amount. Administer by subcutaneous injection 5 mg daily for 6 days, and thereafter, every other day for 8 days. In less severe conditions, shorter courses of therapy may be indicated.
(ii) Indications for use. It is used for the relief of inflammation associated with ankylosing spondylitis, spondylosis, and disc disease. When severe nerve damage is present, response will occur much more slowly, if at all.
91. In § 522.1660a, in paragraph (b), remove “000069” and add “054771” after “048164”; and in paragraph (e)(1)(ii), revise the last sentence to read as follows:
§ 522.1660a
Oxytetracycline solution, 200 milligrams/milliliter.
(ii) * * * Milk taken from animals during treatment and for 96 hours after the last treatment must not be used for food.
§ 522.1662a
92. In § 522.1662a, in paragraphs (c)(2), (d)(2), and (e)(2), remove “000069” and in its place add “054771”; and in paragraph (h)(2), remove “055529 and 059130” and in its place add “000859 and 055529”.
§ 522.1662b
93. In paragraph (b) of § 522.1662b, remove “000069” and in its place add “054771”.
94. In § 522.1664, revise paragraph (d)(3) to read as follows:
§ 522.1664
Oxytetracycline and flunixin.
(3) Limitations. Discontinue treatment at least 21 days prior to slaughter of cattle. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.1680
95. In paragraph (b) of § 522.1680, remove “000856,” and add “054771” after “045628,”.
96. Revise § 522.1696 to read as follows:
§ 522.1696
Penicillin G procaine injectable dosage forms.
§ 522.1696a
97. In § 522.1696a, in paragraphs (b)(1) and (3), remove “000856” and in its place add “054771”; and in paragraph (d)(2)(iii), remove “055529, 059130, and 061623” and in its place add “000859, 055529, and 061623”.
§ 522.1696b
98. In § 522.1696b, in paragraphs (b)(1), (d)(2)(i)(A), and (d)(2)(iii)(A), Start Printed Page 16193remove “053501” and in its place add “054771”.
§ 522.1696c
99. In § 522.1696c, in paragraph (b), remove “053501” and in its place add “054771”; remove paragraph (c); and redesignate paragraph (d) as paragraph (c).
100. In § 522.1698, revise the section heading and paragraphs (a), (b), (c)(1)(i), (c)(1)(iii), (c)(2)(i), and (c)(2)(iii) to read as follows:
§ 522.1698
(a) Specifications. Each milliliter of solution contains pentazocine lactate equivalent to 30 milligrams (mg) of pentazocine base.
(i) Amount. Administer 0.15 mg pentazocine base per pound of body weight daily by intravenous or intramuscular injection. In cases of severe pain, a second dose is recommended by intramuscular injection 10 to 15 minutes after the initial dose at the same level.
(i) Amount. Administer 0.75 to 1.50 mg of pentazocine base per pound of body weight by intramuscular injection.
101. Revise § 522.1704 to read as follows:
§ 522.1704
(a) Specifications. Each milliliter of solution contains 64.8 milligrams (mg) of sodium pentobarbital.
(c) Conditions of use—(1) Amount. The drug is administered intravenously “to effect”. For general surgical anesthesia, the usual dose is 11 to 13 mg per pound of body weight. For sedation, the usual dose is approximately 2 mg per pound of body weight. For relieving convulsive seizures caused by strychnine in dogs, the injection should be administered intravenously “to effect”. The drug may be administered intraperitoneally. When given intraperitoneally, it is administered at the same dosage level as for intravenous administration.
(2) Indications for use. The drug is indicated for use as a general anesthetic in dogs and cats. Although it may be used as a general surgical anesthetic for horses, it is usually given at a lower dose to cause sedation and hypnosis and may be supplemented with a local anesthetic. It may also be used in dogs for the symptomatic treatment of strychnine poisoning.
102. Revise § 522.1720 to read as follows:
§ 522.1720
(a) Specifications—(1) Each milliliter of solution contains 100 milligrams (mg) of phenylbutazone.
(2) Each milliliter of solution contains 200 mg of phenylbutazone.
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (c) of this section:
(1) No. 054771 for use of product described in paragraph (a)(1) as in paragraph (c) of this section.
(2) Nos. 000061, 000859, 054771, and 061623 for use of product described in paragraph (a)(2) as in paragraph (c) of this section.
(3) Nos. 054628 and 058005 for use of product described in paragraph (a)(2) as in paragraph (c)(2) of this section.
(c) Conditions of use— (1) Dogs—(i) Amount. Administer by intravenous injection 10 mg per pound of body weight daily in three divided doses, not to exceed 800 mg daily regardless of weight. Limit intravenous administration to 2 successive days. Oral medication may follow.
(ii) Indications for use. It is used for the relief of inflammatory conditions associated with the musculoskeletal system.
(2) Horses— (i) Amount. Administer by intravenous injection 1 to 2 grams (g) per 1,000 pounds of body weight daily in three divided doses, not to exceed 4 g daily. Limit intravenous administration to not more than 5 successive days.
(ii) Indications for use. For the relief of inflammatory conditions associated with the musculoskeletal system.
103. In § 522.1820, revise the section heading and paragraph (c) to read as follows:
§ 522.1820
Pituitary luteinizing hormone powder for injection.
(c) Conditions of use— (1) Amount. Cattle and horses: 25 milligrams; swine: 5 milligrams; sheep: 2.5 milligrams; and dogs: 1.0 milligram. Preferably given by intravenous injection, it may be administered subcutaneously. Treatment may be repeated in 1 to 4 weeks, or as indicated.
(2) Indications for use. As an aid in the treatment of breeding disorders related to pituitary hypofunction in cattle, horses, swine, sheep, and dogs.
104. Revise § 522.1862 to read as follows:
§ 522.1862
Pralidoxime powder for injection.
(a) Specifications. Each vial contains 1 gram (g) of pralidoxime chloride powder for mixing with 20 cubic centimeters of sterile water for injection. Each milliliter of constituted solution contains 50 milligrams (mg) pralidoxime chloride.
(c) Conditions of use— (1) Amount. Administer as soon as possible after exposure to the poison. Before administration of the sterile pralidoxime chloride, atropine is administered intravenously at a dosage rate of 0.05 mg per pound of body weight, followed by administration of an additional 0.15 mg of atropine per pound of body weight administered intramuscularly. Then the appropriate dosage of sterile pralidoxime chloride is administered slowly intravenously. The dosage rate for sterile pralidoxime chloride when administered to horses is 2 g per horse. When administered to dogs and cats, it is 25 mg per pound of body weight. For small dogs and cats, sterile pralidoxime chloride may be administered either intraperitoneally or intramuscularly. A mild degree of atropinization should be maintained for at least 48 hours. Following severe poisoning, a second dose of sterile pralidoxime chloride may be given after 1 hour if muscle weakness has not been relieved.
(2) Indications for use. It is used in horses, dogs, and cats as an antidote in the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity in horses, dogs, and cats. Start Printed Page 16194
105. Revise § 522.1881 to read as follows:
§ 522.1881
Prednisolone acetate.
(a) Specifications. Each milliliter of suspension contains 25 milligrams (mg) of prednisolone acetate.
(c) Conditions of use—(1) Amount. The drug is administered to horses intra-articularly at a dosage level of 50 to 100 mg. The dose may be repeated when necessary. The drug is administered to dogs and cats intramuscularly at a dosage level of 10 to 50 mg. The dosage may be repeated when necessary. If the condition is of a chronic nature, an oral corticosteroid may be given as a maintenance dosage. The drug may be given intra-articularly to dogs and cats at a dosage level of 5 to 25 mg. The dose may be repeated when necessary after 7 days for two or three doses.
(2) Indications for use. The drug is indicated in the treatment of dogs, cats, and horses for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and postoperatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.
106. Revise § 522.1884 to read as follows:
§ 522.1884
Prednisolone sodium succinate.
(a) Specifications. Each milliliter of prednisolone sodium succinate injection contains: Prednisolone sodium succinate equivalent in activity to 10, 20, or 50 milligrams (mg) of prednisolone.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter for products containing 10, 20, and 50 mg equivalent prednisolone activity per milliliter for use in horses, dogs, and cats as provided in paragraphs (c)(1)(i), (ii), and (iii) of this section.
(c) Conditions of use— (1) Amount and indications for use—(i) Horses. Administer 50 to 100 mg as an initial dose by intravenous injection over a period of one-half to 1 minute, or by intramuscular injection, and may be repeated in inflammatory, allergic, or other stress conditions at intervals of 12, 24, or 48 hours, depending upon the size of the animal, the severity of the condition and the response to treatment.
(ii) Dogs. Administer by intravenous injection at a range of 2.5 to 5 mg per pound of body weight as an initial dose followed by maintenance doses at 1, 3, 6, or 10 hour intervals, as determined by the condition of the animal, for treatment of shock.
(iii) Dogs and cats. Administer by intramuscular injection for treatment of inflammatory, allergic, and less severe stress conditions, where immediate effect is not required, at 1 to 5 mg ranging upward to 30 to 50 mg in large breeds of dogs. Dosage may be repeated in 12 to 24 hours and continued for 3 to 5 days if necessary. If permanent corticosteroid effect is required, oral therapy with prednisolone tablets may be substituted.
(2) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
107. Revise § 522.1885 to read as follows:
§ 522.1885
Prednisolone tertiary butylacetate.
(a) Specifications. Each milliliter of suspension contains 20 milligrams (mg) of prednisolone tertiary butylacetate.
(c) Conditions of use—(1) Amount—(i) Horses: Administer by intramuscular injection 100 to 300 mg or by intrasynovial injection at a dosage level of 50 to 100 mg. Retreatment of horses in 24 to 48 hours may be necessary, depending on the general condition of the animal and the severity and duration of the disease.
(ii) Dogs and cats: Administer by intramuscular injection 1 mg per 5 pounds of body weight or intrasynovially at a dosage level of 10 to 20 mg.
(2) Indications for use. It is used as an anti-inflammatory agent in horses, dogs, and cats.
108. Revise § 522.1890 to read as follows:
§ 522.1890
Sterile prednisone suspension.
(a) Specifications. Each milliliter of suspension contains 10 to 40 milligrams (mg) of prednisone.
(c) Conditions of use—(1) Amount—(i) Horses. Administer 100 to 400 mg by intramuscular injection, repeating if necessary.
(ii) Dogs and cats. Administer 0.25 to 1.0 mg per pound of body weight by intramuscular injection for 3 to 5 days or until a response is noted. Treatment may be continued with an orally administered dose.
(2) Indications for use. It is used for conditions requiring an anti-inflammatory agent.
109. Revise § 522.1920 to read as follows:
§ 522.1920
Prochlorperazine and isopropamide.
(a) Specifications. Each milliliter of solution contains prochlorperazine edisylate equivalent to 4 milligrams (mg) prochlorperazine and isopropamide iodide equivalent to 0.28 mg of isopropamide.
(c) Conditions of use—(1) Amount. (i) Dosage is administered by subcutaneous injection twice daily as follows:
Weight of animal in pounds
Dosage in milliliters
Up to 4 0.25
5 to 14 0.5-1
15 to 30 2-3
30 to 45 3-4
45 to 60 4-5
Over 60 6
(ii) Following the last injection, administer prochlorperazine and isopropamide sustained release capsules as indicated.
(2) Indications for use. For use in dogs and cats in which gastrointestinal disturbances are associated with emotional stress.
110. In § 522.1940, in paragraph (a)(1), remove “000856” and in its place add “054771”.
111. In § 522.1962, in paragraph (b)(1), remove “000856” and in its place add Start Printed Page 16195“054771”; and revise the section heading and paragraph (c)(1)(iii) to read as follows:
§ 522.1962
Promazine.
112. Revise § 522.2002 to read as follows:
§ 522.2002
Propiopromazine.
(a) Specifications. Each milliliter of solution contains 5 or 10 milligrams (mg) propiopromazine hydrochloride.
(c) Conditions of use in dogs and cats—(1) Amounts and indications for use. Administer 0.05 to 0.5 mg per pound of body weight by intravenous or intramuscular injection for tranquilization. Administer 0.25 mg per pound of body weight by intravenous injection as a preanesthetic.
113. In § 522.2005, in paragraph (b)(3), remove “000856” and in its place add “054771”; and add paragraph (c)(3) to read as follows:
§ 522.2005
114. Revise § 522.2012 to read as follows:
§ 522.2012
Prostalene.
(a) Specifications. Each milliliter of solution contains 1 milligram of prostalene.
(b) Sponsor. No. 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer 5 micrograms per kilogram of body weight as a single subcutaneous injection.
(2) Indications for use. For the control of estrus in mares.
115. Revise § 522.2063 to read as follows:
§ 522.2063
Pyrilamine.
(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of pyrilamine maleate.
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for uses in paragraph (c) of this section.
(1) No. 000061 for use as in paragraph (c)(1)(i), (2), and (3) of this section.
(2) No. 061623 for use as in paragraph (c)(1)(ii), (2), and (3) of this section.
(c) Conditions of use—(1) Amount—(i) Horses, 40 to 60 mg per 100 pounds (lbs) body weight; foals, 20 mg/100 lbs body weight. Administer by intramuscular, subcutaneous, or intravenous injection. Dosage may be repeated every 6 to 12 hours whenever necessary.
(ii) Horses, 40 to 60 mg/100 lbs body weight; foals, 20 mg/100 lbs body weight. Administer by slow intravenous injection. Dosage may be repeated every 6 to 12 hours if necessary.
(2) Indications for use. It is intended for treating horses in conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.
116. In § 522.2076, revise paragraph (c)(3) to read as follows:
117. In § 522.2100, revise the section heading and paragraphs (a)(1), (a)(3), (b)(1), (b)(3), and (d)(2) to read as follows:
§ 522.2100
Selenium and vitamin E.
(a)(1) Specifications. Each milliliter of emulsion contains 5.48 milligrams (mg) sodium selenite (equivalent to 2.5 mg selenium) and 50 mg of vitamin E (68 I.U.) (as d-alpha tocopheryl acetate).
(3) Conditions of use in horses—(i) Amount. Administer 1 milliliter (mL) per (/) 100 pounds (lbs) of body weight by intravenous injection or by deep intramuscular injection in divided doses in two or more sites in the gluteal or cervical muscles. Administration may be repeated at 5 to 10 day intervals.
(ii) Indications for use. For the prevention and treatment of selenium-tocopherol deficiency syndrome in horses.
(b)(1) Specifications. Each milliliter contains 2.19 mg of sodium selenite (equivalent to 1 mg of selenium), 50 mg of vitamin E (68 I.U.) (as d-alpha tocopheryl acetate).
(3) Conditions of use in dogs—(i) Amount. Administer by subcutaneous or intramuscular injection in divided doses in two or more sites at 1 mL/20 lbs of body weight with a minimum dosage of 1/4 mL and a maximum dosage of 5 mL. The dose is repeated at 3-day intervals until a satisfactory therapeutic response is observed. A maintenance regimen is then initiated which consists of 1 mL per 40 lbs of body weight with a minimum dosage of 1/4 mL which is repeated every 3 days or 7 days, or longer, as required to maintain continued improvement or an asymptomatic condition; or the drug may be used in capsule form for oral maintenance therapy.
(ii) Indications for use. As an aid in alleviating and controlling inflammation, pain, and lameness associated with certain arthropathies in dogs.
(2) Sponsors. See Nos. 000061 and 054771 in § 510.600(c) of this chapter.
§ 522.2120
118. In paragraph (b) of § 522.2120, remove “000009” and in its place add “054771”.
§ 522.2121
119. In paragraph (b) of § 522.2121, remove “000009” and in its place add “054771”.
120. Revise § 522.2150 to read as follows:
§ 522.2150
(a) Specifications. Each milliliter of suspension contains 50 milligrams (mg) of stanozolol.
(c) Conditions of use—(1) Amount—(i) Dogs and cats. For cats and small breeds of dogs: 25 mg. For larger dogs: 50 mg. Administer by deep intramuscular injection in the thigh at weekly intervals, for several weeks.Start Printed Page 16196
(ii) Horses. Administer 25 mg per 100 pounds of body weight by deep intramuscular injection in the gluteal region at weekly intervals, for not more than 4 weeks.
(2) Indications for use. For use as an anabolic steroid treatment.
121. Revise § 522.2220 to read as follows:
§ 522.2220
(1) 100 milligrams (mg) of sulfadimethoxine sodium.
(2) 400 mg of sulfadimethoxine sodium.
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (d) of this section.
(1) No. 054628 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section.
(2) No. 054771 for use of the product described in paragraph (a)(2) as in paragraphs (d)(2), (3), and (4) of this section.
(3) Nos. 000859, 057561, and 061623 for use of the product described in paragraph (a)(2) as in paragraph (d)(4) of this section.
(c) Related tolerances. See § 556.640 of this chapter.
(d) Conditions of use— (1) Dogs—(i) Amount. Administer by subcutaneous, intramuscular, or intravenous injection at an initial dose of 25 mg per pound of body weight followed by 12.5 mg per pound of body weight every 24 hours thereafter. Continue treatment until the animal is free from symptoms for 48 hours.
(ii) Indications for use. For use in the treatment of sulfadimethoxine-susceptible bacterial infections in dogs.
(2) Dogs and cats—(i) Amount. Administer by intravenous or subcutaneous injection at an initial dose of 55 mg per kilogram of body weight followed by 27.5 mg per kilogram of body weight every 24 hours.
(ii) Indications for use. For the treatment of respiratory, genitourinary tract, enteric, and soft tissue infections when caused by Streptococci, Staphylococci, Escherichia, Salmonella, Klebsiella, Proteus, or Shigella organisms sensitive to sulfadimethoxine, and in the treatment of canine bacterial enteritis associated with coccidiosis and canine Salmonellosis.
(3) Horses—(i) Amount. Administer by intravenous injection at an initial dose of 55 mg per kilogram of body weight followed by 27.5 mg per kilogram of body weight every 24 hours until the patient is asymptomatic for 48 hours.
(ii) Indications for use. For the treatment of respiratory disease caused by Streptococcus equi (strangles).
(4) Cattle—(i) Amount. Administer an initial dose of 25 mg per pound of body weight by intravenous injection followed by 12.5 mg per pound of body weight every 24 hours until the animal is asymptomatic for 48 hours.
(ii) Indications for use. For the treatment of bovine respiratory disease complex (shipping fever complex) and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; necrotic pododermatitis (foot rot) and calf diphtheria caused by Fusobacterium necrophorum sensitive to sulfadimethoxine.
(iii) Limitations. Milk taken from animals during treatment and for 60 hours (5 milkings) after the latest treatment must not be used for food. Do not administer within 5 days of slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
122. Revise § 522.2240 to read as follows:
§ 522.2240
(a) Specifications. The drug is an aqueous solution of sulfaethoxypyridazine.
(c) Related tolerances. See § 556.650 of this chapter.
(d) Conditions of use in cattle—(1) Amount. Administer 2.5 grams per 100 pounds of body weight per day by intravenous injection for not more than 4 days; or first treatment may be followed by 3 days of treatment with sulfaethoxypyridazine in drinking water or tablets in accordance with §§ 520.2240a(e) and 520.2240b(e) of this chapter.
(2) Indications for use. For treatment of respiratory infection (pneumonia, shipping fever), foot rot, calf scours; as adjunctive therapy in septicemia accompanying mastitis and metritis.
(3) Limitations. Do not treat within 16 days of slaughter. Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.2340
123. In paragraph (b) of § 522.2340, remove “000069” and in its place add “054771”.
§ 522.2404
124. In paragraph (b) of § 522.2404, remove “000856” and in its place add “054771”.
125. Revise § 522.2424 to read as follows:
§ 522.2424
Thiamylal.
(a) Specifications. The drug is a sterile powder. It is reconstituted with sterile distilled water, water for injection, or sodium chloride injection, to a desired concentration of 0.5 to 4 percent sodium thiamylal.
(b) Sponsors. See Nos. 054628 and 054771 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. Administer by intravenous injection to effect. The average single dose is:
(i) Dogs and cats: 8 milligrams (mg) per pound of body weight (when used with a preanesthetic, generally one-half the normal dose).
(ii) Swine: 40 mg per 5 pounds (lbs) of body weight.
(iii) Horses: Light anesthesia, 1 gram per 500 lbs to 1,100 lbs of body weight; deep anethesia, 1 gram per 300 lbs of body weight (40 mg/12 lbs of body weight).
(iv) Cattle: Short duration, 20 mg/5 lbs of body weight; longer duration, 40 mg/7 lbs of body weight.
(2) Indications for use. It is used as an ultra-short-acting anesthetic in dogs, cats, swine, horses, and cattle.
126. Revise § 522.2444 to read as follows:
§ 522.2444
Thiopental injectable dosage forms.
127. Revise § 522.2444a to read as follows:
§ 522.2444a
Thiopental powder for injection.
(a) Specifications. The drug contains sodium thiopental powder for constitution with sterile water for injection.Start Printed Page 16197
(c) Conditions of use in dogs and cats—(1) Amount. Administer by intravenous injection as follows:
(i) 6 to 9 milligrams (mg) per pound of body weight for brief anesthesia (6 to 10 minutes).
(ii) 10 to 12 mg per pound of body weight for anesthesia of 15 to 25 minutes duration.
(2) Indications for use. It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical and other procedures. It is also used to induce anesthesia in dogs and cats which then have surgical anesthesia maintained by use of a volatile anesthetic.
128. Revise § 522.2444b to read as follows:
§ 522.2444b
Thiopental and pentobarbital powder for injection.
(a) Specifications. Each gram of powder contains 750 milligrams (mg) of sodium thiopental and 250 mg of sodium pentobarbital powder for dilution with sterile water for injection.
(b) Sponsor. See No. 061623 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. For total anesthesia, it is given at approximately 10 to 12 mg per pound of body weight over a period of 3.5 to 5 minutes. When preanesthetic medication is used, wait at least an hour before administering thiopental and sodium pentobarbital for injection, and the dosage necessary for anesthesia is reduced. Usually 1/2 to 2/3 the normal amount is adequate.
(2) Indications for use. It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical procedures.
129. Revise § 522.2470 to read as follows:
§ 522.2470
Tiletamine and zolazepam for injection.
(a) Specifications. The drug is a sterile powder. Each milliliter of constituted solution contains tiletamine hydrochloride equivalent to 50 milligrams (mg) of tiletamine base and zolazepam hydrochloride equivalent to 50 mg of zolazepam base.
(c) Conditions of use in dogs and cats—(1) Amount. Expressed as milligrams of the drug combination:
(i) Healthy dogs: An initial intramuscular dosage of 3 to 4.5 mg per pound of body weight for diagnostic purposes; 4.5 to 6 mg per pound of body weight for minor procedures of short duration such as repair of lacerations and wounds, castrations, and other procedures requiring mild to moderate analgesia. Supplemental doses when required should be less than the initial dose and the total dose given should not exceed 12 mg per pound of body weight. The maximum total safe dose is 13.6 milligrams per pound of body weight.
(ii) Healthy cats: An initial intramuscular dosage of 4.4 to 5.4 mg per pound of body weight for such procedures as dentistry, treatment of abscesses, foreign body removal, and related types of surgery; 4.8 to 5.7 mg per pound of body weight for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations, and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg per pound of body weight are recommended for ovariohysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg per pound of body weight.
(2) Indications for use. For restraint or for anesthesia combined with muscle relaxation in cats and in dogs for restraint and minor procedures of short duration (30 minutes) requiring mild to moderate analgesia.
130. Revise § 522.2474 to read as follows:
§ 522.2474
Tolazoline.
(a) Specifications. Each milliliter of solution contains tolazoline hydrochloride equivalent to 100 milligrams (mg) of base activity.
(b) Sponsor. See No. 061690 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer slowly by intravenous injection 4 mg per kilogram of body weight or 1.8 mg per pound (4 milliliters (mL) per 100 kilograms or 4 mL per 220 pounds).
(2) Indications for use. For use in horses when it is desirable to reverse the effects of sedation and analgesia caused by xylazine.
131. In paragraph (b)(3) of § 522.2477, remove “000856” and in its place add “054771”.
§ 522.2478
132. In paragraph (b) of § 522.2478, remove “000856” and in its place add “054771”.
133. Revise § 522.2582 to read as follows:
§ 522.2582
(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of triflupromazine hydrochloride.
(c) Conditions of use—(1) Amount—(i) Dogs. Administer by intravenous injection at a dosage of 0.5 to 1 mg per pound of body weight daily, or by intramuscular injection at a dosage of 1 to 2 mg per pound of body weight daily.
(ii) Cats. Administer by intramuscular injection at a dosage of 2 to 4 mg per pound of body weight daily.
(iii) Horses. Administer by intravenous or intramuscular injection at a dosage of 10 to 15 mg per 100 pounds of body weight daily to a maximum dose of 100 mg.
(2) Indications for use. For use in dogs, cats, and horses to relieve anxiety and to help control psychomotor overactivity as well as to increase the tolerance of animals to pain and pruritus. The drug is indicated in various office and clinical procedures which require the aid of a tranquilizer, antiemetic, or preanesthetic.
134. In § 522.2610, in paragraph (b), remove “000856” and in its place add “054771”; remove paragraph (c); redesignate paragraph (d) as paragraph (c); add new paragraph (c)(1)(iii); and revise newly redesignated paragraph (c)(2)(iii) to read as follows:
§ 522.2610
Trimethoprim and sulfadiazine.
(iii) Limitations. Do not use in horses intended for human consumption. Start Printed Page 16198Federal law restricts this drug to use by or on the order of a licensed veterinarian.
135. In § 522.2615, revise the section heading and paragraphs (a), (b), and (d) to read as follows:
§ 522.2615
Tripelennamine.
(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of tripelennamine hydrochloride.
(d) Conditions of use—(1) Dogs and cats—(i) Amount. Administer 0.5 mg per pound of body weight by intramuscular injection.
(ii) Indications for use. For use in treating conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.
(2) Horses—(i) Amount. Administer 0.5 mg per pound of body weight by intramuscular injection.
(3) Cattle—(i) Amount. Administer 0.5 mg per pound of body weight by intravenous or intramuscular injection.
(iii) Limitations. Treated cattle must not be slaughtered for food during treatment and for 4 days following the last treatment. Milk that has been taken during treatment and for 24 hours (two milkings) after the last treatment must not be used for food. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
136. In § 522.2640, redesignate paragraphs (d) and (e) as paragraphs (c) and (d), respectively; and revise paragraphs (a), (b), and newly designated (d)(1)(iii), (d)(3)(i), and (d)(3)(iii) to read as follows:
(a) Specifications. Each milliliter of solution contains 50 or 200 milligrams of tylosin activity (as tylosin base).
(1) No. 000986 for use in paragraphs (d)(1), (2), and (3) of this section.
(2) No. 000010 for use as in paragraphs (d)(1) and (2) of this section.
(iii) Limitations. Administer intramuscularly for not more than 5 consecutive days. Continue treatment 24 hours after symptoms disappear. Use a 50-milligram-per-milliliter solution for calves weighing less than 200 pounds. Do not inject more than 10 milliliters per site. Do not administer within 21 days of slaughter. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(i) Amount. Administer 3 to 5 milligrams per pound of body weight by intramuscular injection at 12- to 24-hour intervals. Use 50 milligram per milliliter solution only.
137. In § 522.2662, revise paragraph (d)(2)(iii) to read as follows:
§ 522.2662
(iii) Limitations. Do not use in horses intended for human consumption.
138. In § 522.2670, revise the section heading and paragraph (a) to read as follows:
§ 522.2670
(a) Specifications. Each milliliter of solution contains either 2 or 5 milligrams of yohimbine (as hydrochloride).
[FR Doc. 2014-06131 Filed 3-24-14; 8:45 am]